Clinical Trial Update: Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

View source ↗

Summary

Biomarker findings from a completed trial of high-dose interferon therapy in patients with high-risk melanoma are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Intron A (interferon alfa-2b)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Melanoma (Skin) | Status: COMPLETED